Drugs / Artesunate-Pyronaridin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT04778813 | Jun → Dec 2021 | malaria | Centre national de recherche et de formation sur le paludisme | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Artesunate-Pyronaridin | “Artesunate-Pyronaridin (As-Pyr)” NCT04778813 ↗ |
| Known as | As-Pyr | “Artesunate-Pyronaridin (As-Pyr)” NCT04778813 ↗ |
| Route | Oral | “The tablets will be given orally according to patients' age and under supervision of study team as follows.” NCT04778813 ↗ |